In COMMANDER-HF, conducted in patients with recently decompensated heart failure treated with rivaroxaban, no significant impact on the primary outcome was demonstrated. Results are discussed with John Cleland (National Heart and Lung Institute, Imperial College London) at the ESC Congress 2018.